GID4

Across TCGA pan-cancer cohorts, GID4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GID4 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher GID4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GID4 expression acts as an unfavorable survival marker.

COAD, LUSC, and BLCA are the cancer types where GID4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.172	0.870	<.001	16	view →
LUSC	OS	Median	All	0.152	0.762	.017	12	view →
BLCA	DFS	Median	All	0.179	0.625	.029	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GID4–COAD (OS)

Open the COAD breakdown →